Because more than 90% of VMAT2s are located in the dopamine nerve terminals [28], in vivo estimation of VMAT2 density using 11C-(+)-DTBZ PET has attracted considerable interest for the diagnosis and management of PD and associated nigrostriatal degeneration disorders. Here, SLC18A2 is linked to Parkinson disease.